Lundbeck

Lundbeck is a global pharmaceutical company specializing in the research, development, manufacturing, and commercialization of treatments for brain diseases.

Established in 1915 by Hans Lundbeck in Copenhagen, Denmark, the company has dedicated over 70 years to advancing neuroscience.

Their aim is to improve the lives of individuals affected by various neurological and psychiatric conditions.

With a workforce of approximately 5,600 employees across more than 50 countries, Lundbeck's products are registered in over 100 nations. This reflects its extensive global reach.

The company's portfolio includes treatments for conditions such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and migraine.

Notably, Lundbeck's products reach more than 8 million people daily, underscoring the significant impact of its therapies worldwide.

Focus and Operations

Lundbeck is committed to brain health, with a specialized focus on central nervous system disorders.

The company operates research centers in Denmark and the United States, with production facilities located in Denmark, France, and Italy.

In the U.S., Lundbeck has a significant presence including headquarters in Deerfield, Illinois, and research facilities in La Jolla, California, and Bothell, Washington.

The Lundbeck Foundation

The Lundbeck Foundation owns approximately 70% of the company's shares and plays a pivotal role in supporting Lundbeck's mission.

It annually grants about DKK 500 million to support medical research as well as educational and communication activities.

This reinforces the company's dedication to advancing brain health and transforming lives.

Locations

• Little Rock, AR, USA
• Macon, GA, USA
• Fargo, ND, USA
• Newport News, VA, USA

In summary, Lundbeck stands as a dedicated leader in brain health, continually striving to develop innovative treatments that address the complex challenges of neurological and psychiatric disorders.

This work enhances the quality of life for individuals worldwide.